Johnson & Johnson's Weak Pharma Revenue Could Spell Doom For Rest Of Sector

Published: Apr 19, 2017

Johnson & Johnson ( JNJ) shares closed down about 3% after the company reported first quarter revenue that missed analysts' expectations due to lighter than expected pharmaceutical sales.

The company reported first quarter earnings of $1.83 per share on revenue of $17.7 billion vs. Wall Street expectations of earnings of $1.77 per share on revenue of $18.04 billion. The company said U.S. pharmaceutical sales fell about 3% quarter-over-quarter to about $4.87 billion.

Back to news